Targeted therapies, such as BRAF/MEK inhibitors in melanoma and TKIs, optimize ICI responses by modulating the TME and gut microbiome, which are key factors that improve ICI responses with certain bacterial strains that enhance antitumor immune activity. This evidence concerns the gene BRAF and melanoma.